Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Mind Medicine Inc

Company price
None USD 0.00(0%)
Last update at 2026-02-19T21:03:11.179915Z
Market Cap
600.49M

Momentum Score

…

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.41
Low
12.22
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.18
ROE
-83.59%
Net Debt
-85.58M
ROCE
-71.87%
Diluted EPS TTM
-2.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -56.80M -94.19M -33.94M -1.23M -0.91M
Net income -47.26M -93.04M -34.10M -1.23M -0.91M
Selling general administrative 30.16M 59.06M 14.40M 0.51M 0.91M
Reconciled depreciation 3.18M 2.62M 0.00M - -
Ebit -66.33M -96.36M -33.77M -18.39M -
Ebitda -74.37M -93.75M -33.03M - -
Depreciation and amortization -8.04M 2.62M 0.74M - -
Non operating income net other 9.54M -0.34M - - -
Operating income -66.33M -96.36M -33.03M -1.23M -0.91M
Other operating expenses 66.33M 93.85M 33.03M - -
Interest expense 1.50M 0.36M 0.16M 0.00M 0.00M
Tax provision 0.00M -1.16M 0.00M - -
Interest income - - 0.73M 0.03M 0.00M
Net interest income 1.50M -0.36M -0.16M - -
Income tax expense -9.54M -1.16M 0.16M - -
Total revenue 0.00M 0.00M 0.00M - -
Total operating expenses 66.33M 93.85M 33.03M - -
Total other income expense net 9.54M 2.17M -0.91M - -
Net income from continuing ops -56.80M -93.04M -33.94M - -
Net income applicable to common shares -56.80M -93.04M -33.94M -18.34M -0.91M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 124.54M 169.99M 164.00M 81.52M 11.96M
Intangible assets 0.53M 3.69M 6.87M 4.67M 5.22M
Other current assets 4.17M 3.91M 3.68M 1.43M 3.69M
Total liab 46.41M 19.08M 12.34M 5.65M 1.96M
Total stockholder equity 78.13M 150.92M 151.66M 75.87M 10.00M
Other current liab 28.11M 15.71M 6.23M 0.99M -
Common stock - - - 105.60M 15.32M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -290.20M -194.47M -137.67M -44.64M -5.47M
Other liab - 1.18M 1.93M 2.64M -
Good will 19.92M 19.92M 19.92M 0.00M -
Other assets 0.00M 0.33M - - -
Cash 99.70M 142.14M 133.54M 80.09M -
Total current liabilities 32.25M 17.89M 10.41M 3.01M 1.96M
Net debt -85.58M -142.07M -133.54M -80.09M -
Short term debt - 0.07M - - -
Short long term debt total 14.13M 0.07M - - -
Other stockholder equity 367.99M 344.76M 288.29M 120.22M 0.15M
Total current assets 103.87M 146.06M 137.22M 81.52M 6.74M
Net tangible assets - 127.31M 124.88M 75.87M 4.78M
Long term debt 14.13M - - - -
Accounts payable 4.14M 2.11M 4.18M 2.02M 1.18M
Accumulated other comprehensive income 0.34M 0.63M 1.05M 0.28M -
Retained earnings total equity - -194.47M -137.67M - -
Non currrent assets other 0.22M 0.33M - - -
Non current assets total 20.67M 23.94M 26.79M 0.00M -
Capital lease obligations - 0.07M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00M -0.30M 0.00M - -
Change to liabilities -2.47M 5.91M 0.54M 2.09M -
Total cashflows from investing activities - -0.30M -0.30M -0.30M 0.57M
Total cash from financing activities 59.05M 98.82M 96.70M 16.97M 0.33M
Change to operating activities -1.73M 1.75M 1.52M 1.22M -
Net income -56.80M -93.04M -33.94M -18.34M -0.91M
Change in cash 8.60M 53.45M 73.39M 11.49M 0.16M
Begin period cash flow 133.54M 80.09M 6.70M - -
End period cash flow 142.14M 133.54M 80.09M 6.70M -
Total cash from operating activities -50.14M -45.82M -23.60M -5.48M -0.77M
Issuance of capital stock 42.30M 81.92M 71.99M - -
Depreciation 3.18M 2.62M 0.55M 0.02M 0.01M
Other cashflows from investing activities - -0.30M - 0.11M 1.68M
Change to account receivables - - -0.01M -0.01M -
Sale purchase of stock 60.96M 98.82M 97.38M 0.32M 0.35M
Other cashflows from financing activities 16.75M 16.90M 24.71M -0.40M -
Change to netincome 5.72M 41.56M 8.28M 9.55M -
Capital expenditures 0.00M 0.00M 0.00M 0.34M 1.11M
Cash flows other operating 0.23M -2.88M - - -
Cash and cash equivalents changes 8.91M 52.70M - - -
Change in working capital -3.78M 1.88M 2.06M 0.23M -0.02M
Stock based compensation 13.71M 42.72M 7.41M - -
Other non cash items -6.45M 1.16M 0.87M - -
Free cash flow -50.14M -45.82M -23.60M - -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
2.85
0.30%
960.62 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Mind Medicine Inc

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

One World Trade Center, New York, NY, United States, 10007

212-220-6633

57

Name Title Year Born
Mr. Robert Barrow CEO & Director 1989
Dr. Miriam Halperin Wernli Ph.D. Exec. Pres 1953
Dr. Daniel Rollings Karlin M.A., M.D. Chief Medical Officer 1980
Dr. Scott M. Freeman M.D. Co-Founder & Clinical Advisor 1957
Mr. Leonard Latchman Co-founder NA
Mr. Schond L. Greenway Chief Financial Officer 1972
Ms. Carrie F. Liao CPA, CGMA VP, Corp. Controller & Accounting Principal NA
Ms. Wong Hu J.D. Chief Legal Officer & Corp. Sec. 1970
Dr. Francois P. Lilienthal M.B.A., M.D. Chief Commercial Officer NA
Mr. Schond L. Greenway M.B.A. Chief Financial Officer 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…